廣告
香港股市 將收市，收市時間：1 小時 32 分鐘

  • 恒指

    17,987.83
    -39.88 (-0.22%)
     

  • 國指

    6,432.43
    -8.73 (-0.14%)
     

  • 上證綜指

    2,936.30
    -26.79 (-0.90%)
     

  • 滬深300

    3,441.61
    -35.20 (-1.01%)
     

  • 美元

    7.8067
    -0.0010 (-0.01%)
     

  • 人民幣

    0.9296
    +0.0005 (+0.05%)
     

  • 道指

    39,411.21
    +260.88 (+0.67%)
     

  • 標普 500

    5,447.87
    -16.75 (-0.31%)
     

  • 納指

    17,496.82
    -192.54 (-1.09%)
     

  • 日圓

    0.0487
    +0.0000 (+0.06%)
     

  • 歐元

    8.3808
    +0.0013 (+0.02%)
     

  • 英鎊

    9.9030
    0.0000 (0.00%)
     

  • 紐約期油

    81.63
    0.00 (0.00%)
     

  • 金價

    2,337.40
    -7.00 (-0.30%)
     

  • Bitcoin

    61,072.80
    -1,262.00 (-2.02%)
     

  • CMC Crypto 200

    1,267.77
    +18.65 (+1.49%)
     

Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial

Vandana Singh
·1 分鐘文章

Vaxxinity Inc (NASDAQ: VAXX) unveiled results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson's disease (PD).

UB-312 is a synthetic peptide vaccine targeting aggregated forms of aSyn, which plays a central role in PD development and progression.

UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the trial's primary objectives.

92% of patients (12 out of 13) who completed dosing with UB-312 developed anti-aSyn antibodies.

The results demonstrate important features for immunotherapy against PD and represent a proof-of-principle for Vaxxinity's platform in chronic disease.

廣告

UB-312 was well-tolerated, and antibodies were detectable in cerebrospinal fluid.

UB-312 safely broke immune tolerance, induced antibodies against toxic forms of alpha-synuclein, and showed potential target engagement in the periphery and crossing the blood-brain barrier.

The trial was not designed to measure differences in PD progression between UB-312 and placebo groups.

The Michael J. Fox Foundation is funding a collaborative project to evaluate the potential of UB-312 further and characterize the produced anti-aSyn antibodies.

Price Action: VAXX shares are down 2.38% at $2.05 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.